Becker's Healthcare March 26, 2025
Cameron Cortigiano

Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.

The funding will be used to advance the company’s pipeline of therapies to treat degenerative eye diseases, starting with age-related macular degeneration, according to a March 25 news release from the company.

Character Biosciences has partnered with more than 150 ophthalmology treatment centers across...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
Fortune: The 61 most innovative companies in healthcare
Personalized Gene Therapy for All
Bariatric surgery’s next act: What 3 leaders expect
How Real-World Data Can Support Label Extension And Safer Use Of Novel Therapies

Share This Article